• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Norlevo
    / CTS

    Active Ingredient
    Levonorgestrel 0.75 mg, 1.5 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    1 X 1.5 mg

    partial basket chart 22495 14508

    Related information


    One tablet to be taken as soon as possible, preferably within 12 hours after unprotected intercourse, and no longer than 72 hours after.
    Use in children and adolescents: NorLevo 1.5 mg is not intended for users who have not yet had their first menstrual cycle (menarche).


    The medicine is intended as an emergency contraceptive when taken up to 72 hours (3 days) after having unprotected intercourse, or if your routine contraceptive methods have failed.
    This medical product prevents pregnancy in 99% of the situations when it is taken within 72 hours from the date of unprotected intercourse.
    This medical product will not prevent pregnancy in every instance. The sooner Levonorgestrel is taken after intercourse, the more effective it will be. It is preferable to take this medical product within 12 hours after unprotected intercourse rather than wait until the third day.


    Hypersensitivity to levonorgestrel or any of the excipients. Should not be used if more than 72 hours have passed after unprotected sexual intercourse.

    Special Precautions

    Patients under 14 years of age should consult with a doctor before starting treatment.
    Not recommended in patients with disease of the small bowel (such as Crohn’s disease) that inhibits the absorption of the medicine.
    Patients with severe liver dysfunction.
    Patients with history of ectopic pregnancy (where the baby develops outside the uterus).
    Patients who suffered from inflammation of the fallopian tubes.

    Side Effects

    Very common: Feeling sick (nausea), Abnormal bleeding until getting the menstrual period, Lower abdominal pain, Tiredness, Headache.
    Common: Vomiting, Changes in menstrual period, Tender breasts, diarrhea, dizziness.
    See package insert (OTC).

    Drug interactions

    Barbiturates and other medicines used to treat epilepsy (e.g., primidone,
    phenytoin, and carbamazepine).
    Medicines used to treat tuberculosis (e.g., rifampicin and rifabutin).
    Medicines for the treatment of AIDS (e.g., ritonavir, efavirenz).
    Medicines for the treatment of fungal infections (e.g., griseofulvin).
    Herbal remedies containing hypericum (St. John’s wort)

    Pregnancy and Lactation

    Pregnancy: This medicine is contraindicated during pregnancy.
    There is no evidence that NorLevo 1.5 mg harms the fetus and fetal development if it has been taken as instructed.
    Breastfeeding: Levonorgestrel passes into breast milk. Patientes advised to take the medicine immediately after breastfeeding and avoid breastfeeding for 8 hours after taking the tablet.

    Laboratoire HRA Pharma
    Licence holder